Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas-Vical’s CMV Vaccine Disappoints in PII for Kidney Transplant Patients
September 21, 2016
- In a Turnaround, EU Panel Backs Takeda’s Ninlaro for Conditional Approval
September 21, 2016
- Entyvio Shows Favorable Benefits in Both TNF-Naïve, TNF-Failed UC Patients
September 21, 2016
- Meiji Seika Pharma to Establish Medical Science Promotion Office in October
September 21, 2016
- Nichi-Iko to Set up Biosimilar Dept. in October to Push Remicade Follow-On
September 21, 2016
- Eisai Looks to Achieve CAGR of 55% for Fycompa with Add’l Indications
September 20, 2016
- Ono, NCC Join Hands for Discovery of Anticancer Agents, Biomarker Research
September 20, 2016
- Osaka Univ. Spinoff, Sumitomo Dainippon Ink Joint Research Pact on Antibody-Inducing Peptides
September 20, 2016
- MSD, Kyorin to Copromote Nasonex Nasal Spray
September 16, 2016
- Asahi Kasei Pharma Gets Japan Rights to Basilea’s Antifungal Agent
September 16, 2016
- Lenvatinib Gets EU Nod for RCC: Eisai
September 16, 2016
- Sawai, Tatsumi Kagaku Tie Up on Kipres Generics
September 16, 2016
- Novartis Eager to See More 1st Approvals in Japan despite Pricing Headache
September 14, 2016
- Takeda Returns Rights to MacroGenics’ RA Candidate MGD010
September 14, 2016
- Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
September 14, 2016
- “Regulatory Science Center” to Play Important Role to Establish Next-Generation Treatments: JPMA President
September 13, 2016
- Novartis Paid 13.2 Billion Yen to Doctors, Medical Institutions in 2015
September 13, 2016
- Nippon Shinyaku on Track to Achieve Targets in Midterm Plan with Sales of Selexipag Above Expectations: President
September 12, 2016
- Sales of Ethical Drugs Down 6.4% in July: Crecon Report
September 12, 2016
- Takeda Starts Global PIII for Dengue Vaccine
September 9, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…